JS Link

JS Link Net Debt/Equity

The Net Debt to Equity Ratio of JS Link (127120.KQ) as of Oct 26, 2026 is 0.07. In the previous year, Net Debt to Equity Ratio was 0.58 — a change of -87.32% (lower).

Net Debt/Equity

0.07

YoY

-87.32%

Last updated:

Net Debt to Equity Ratio of JS Link is 2025 0.07 . Net Debt to Equity Ratio of JS Link was 2024 0.58 . It decreases by -87.32% lower compared to the previous year.

The JS Link Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2018
-0.11 KRW
Jan 1, 2019
0.34 KRW
Jan 1, 2020
-0.88 KRW
Jan 1, 2021
-0.13 KRW
Jan 1, 2022
-0.17 KRW
Jan 1, 2023
-0.09 KRW
Jan 1, 2024
0.58 KRW
Jan 1, 2025
0.07 KRW
The JS Link Net Debt/Equity history
YEARNet Debt/EquityYoY
0.07-87.32%
0.58-773.08%
-0.09-49.28%
-0.17+27.18%
-0.13-85.00%
-0.88-362.94%
0.34-408.08%
-0.11-57.06%
-0.25-103.27%
7.76+365.68%
1.67+32.58%
1.26—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JS Link Stock analysis

What does JS Link do? DNA Link, Inc. generates revenue through its genomic analysis services and products. The company offers genome biomarkers excavation products via the enhanced genome integration system (EGIS) brand, which includes high-quality data products, genomic analysis interpretation, and molecular diagnostic kit production technologies. Additionally, DNA Link provides personal genome analysis services under the deoxyribonucleic acid personalized services (DNAGPS) brand, targeting individuals seeking personalized genetic insights. The primary customers for EGIS are healthcare providers and research institutions requiring integrated genomic and clinical data solutions, while DNAGPS serves individual consumers interested in personalized health information. The enhanced genome integration system (EGIS) brand focuses on delivering comprehensive genomic analysis and clinical information integration, catering to the needs of medical professionals and research organizations. DNAGPS targets individual users who want detailed personal genome reports. Both product lines leverage DNA Link's expertise in genomic analysis and molecular diagnostics, ensuring high-quality data and interpretation services. The company's revenue streams are driven by the sale of these branded products to their respective target segments. DNA Link's business model centers around two core product lines: EGIS for professional and institutional clients and DNAGPS for individual consumers. EGIS products are sold to healthcare providers and research institutions that require advanced genomic data analysis and molecular diagnostic solutions. DNAGPS services are marketed directly to consumers seeking personalized genetic information. The company's revenue is derived from the licensing and sale of these branded genomic analysis services and products, with no mention of additional revenue sources in the business description. JS Link is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JS Link stock

Net Debt to Equity Ratio of JS Link is 0.07 in 2025.

Net Debt to Equity Ratio of JS Link changed from 0.58 to 0.07, representing a -87.32% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio JS Link since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's JS Link with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — JS Link

All Key Metrics — JS Link